Drugs for Suppression of Tumorigenicity 12 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 248)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Fesoterodine |
Approved |
Phase 4 |
|
286930-03-8, 286930-02-7 |
6918558 |
Synonyms:
FESO
Fesoterodina
Fesoterodine
Fesoterodine fumarate
|
|
|
2 |
|
Lidocaine |
Approved, Vet_approved |
Phase 4 |
|
137-58-6 |
3676 |
Synonyms:
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
a-Diethylamino-2,6-dimethylacetanilide
ALGRX 3268
ALGRX-3268
ALPHACAINE
alpha-Diethylamino-2,6-dimethylacetanilide
ANESTACON
Astrazeneca brand OF lidocaine
Dalcaine
Dentipatch
Dilocaine
EMBOLEX
IONTOCAINE
Jenapharm brand OF lidocanine hydrochloride
L-Caine
Lidocaina
Lidocaína
LIDOCAINE
Lidocaine carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
|
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
LIDOCATON
Lidoderm
LIDOPEN
Lignocaine
LIGNOCAINE HCL
LIGNOSTAB
LMX 4
Novocol brand OF lidocaine hydrochloride
NSC-40030
Octocaine
ORAQIX
Strathmann brand OF lidocaine hydrochloride
VAGISIL
Xylesthesin
Xylocaine
Xylocaine®
Xylocitin
XYLODASE
Xyloneural
XYLOTOX
ZTLIDO
Α-diethylamino-2,6-dimethylacetanilide
|
|
3 |
|
Prilocaine |
Approved |
Phase 4 |
|
721-50-6 |
4906 |
Synonyms:
2-(Propylamino)-O-propionotoluidide
2-Methyl-alpha-propylaminopropionanilide
2-Methyl-a-propylaminopropionanilide
2-Methyl-α-propylaminopropionanilide
alpha-N-Propylamino-2-methylpropionanilide
a-N-Propylamino-2-methylpropionanilide
ASTRA 1512
Astra 1515
Astra brand OF prilocaine hydrochloride
ASTRA-1512
ASTRA-1515
AstraZeneca brand OF prilocaine hydrochloride
Citanest
Citanest octapressin
Citanest Plain
Delvet brand OF prilocaine hydrochloride
Inibsa brand OF prilocaine hydrochloride
L-67
|
N-(2-Methylphenyl)-2-(propylamino)propanamide
NSC-40027
O-Methyl-2-propylaminopropionanilide
O-Methyl-alpha-propylaminopropionanilide
O-Methyl-a-propylaminopropionanilide
O-Methyl-α-propylaminopropionanilide
Parnell brand OF prilocaine hydrochloride
PRILOCAIN
Prilocaina
PRILOCAINE
PRILOCAÏNE
Prilocaine base
Prilocaine hydrochloride
Prilocainum
PRILOTEKAL
Propitocaine
Xylonest
Α-N-propylamino-2-methylpropionanilide
|
|
4 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
5 |
|
Muscarinic Antagonists |
|
Phase 4 |
|
|
|
6 |
|
Cholinergic Antagonists |
|
Phase 4 |
|
|
|
7 |
|
Cholinergic Agents |
|
Phase 4 |
|
|
|
8 |
|
Anti-Arrhythmia Agents |
|
Phase 4 |
|
|
|
9 |
|
Sodium Channel Blockers |
|
Phase 4 |
|
|
|
10 |
|
Anesthetics, Local |
|
Phase 4 |
|
|
|
11 |
|
Anesthetics |
|
Phase 4 |
|
|
|
12 |
|
Diuretics, Potassium Sparing |
|
Phase 4 |
|
|
|
13 |
|
Iodine |
Approved, Investigational |
Phase 2, Phase 3 |
|
7553-56-2 |
807 |
Synonyms:
Cadex
Diiodine
I2
Iode
Iodine
Iodine 127
Iodine-127
Iodine-molecule
|
Iodio
iodo
Iodum
Jod
Jood
Molecular iodine
NSC-42355
Tincture iodine
|
|
14 |
|
Venlafaxine |
Approved |
Phase 3 |
|
99300-78-4, 93413-69-5 |
5656 |
Synonyms:
1-(2-(dimethylamino)-1-(4-Methoxyphenyl)ethyl)cyclohexanol HCL
1-[2-(DIMETHYLAMINO)-1-(4-METHOXYPHENYL)ETHYL]CYCLOHEXAN-1-OL
ALVENTA XL
AMPHERO XL
BONILUX XL
Cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, hydrochloride
DEPEFEX XL
Dobupal
Efectin
Efexor
EFEXOR XL
Effexor
EFFEXOR XR
Effexor®|WY-45030
Elafax
FORAVEN XL
Hydrochloride, venlafaxine
MENTAVEN XL
POLITID XL
RANFAXINE XL
RODOMEL XL
Sila venlafaxine
Sila-venlafaxine
SUNVENIZ XL
TARDCAPS XL
TIFAXIN XL
|
TONPULAR XL
Trevilor
TRIXAT XL
Vandral
VAXALIN XL
VENAXX XL
VENLABLUE XL
VENLADEX XL
Venlafaxin
Venlafaxina
Venlafaxina [INN-Spanish]
VENLAFAXINE
Venlafaxine [INN:Ban]
VENLAFAXINE HCL
Venlafaxine hydrochloride
Venlafaxinum
Venlafaxinum [INN-Latin]
Venlafexine
VENLALIC XL
VENLANEO XL
VENSIR XL
VEXARIN XL
VIEPAX
VIEPAX XL
WINFEX XL
WY-45030
|
|
15 |
|
Medroxyprogesterone acetate |
Approved, Investigational |
Phase 3 |
|
520-85-4, 71-58-9 |
6279 10631 |
Synonyms:
(6ALPHA)-17-(ACETYLOXY)-6-METHYLPREG-4-ENE-3,20-DIONE
(6α)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione
17 alpha Hydroxy 6 alpha methylprogesterone
17 alpha-Hydroxy-6 alpha-methylprogesterone
17-ACETOXY-6ALPHA-METHYLPROGESTERONE
17-ACETOXY-6Α-METHYLPROGESTERONE
17a-Hydroxy-6a-methylprogesterone
17alpha-Hydroxy-6alpha-methylprogesterone
17ALPHA-HYDROXY-6ALPHA-METHYLPROGESTERONE ACETATE
17-Hydroxy-6alpha-methyl-pregn-4-ene-3,20-dione
17-Hydroxy-6alpha-methylprogesterone
17-Hydroxy-6a-methyl-pregn-4-ene-3,20-dione
17-Hydroxy-6a-methylprogesterone
17-Hydroxy-6α-methyl-pregn-4-ene-3,20-dione
17-Hydroxy-6α-methylprogesterone
17Α-hydroxy-6α-methylprogesterone
17Α-HYDROXY-6Α-METHYLPROGESTERONE ACETATE
6ALPHA-METHYL-17-ACETOXY PROGESTERONE
6-ALPHA-METHYL-17-ALPHA-ACETOXYPROGESTERONE
6alpha-Methyl-17alpha-hydroxyprogesterone
6ALPHA-METHYL-17ALPHA-HYDROXYPROGESTERONE ACETATE
6-ALPHA-METHYL-17-ALPHA-HYDROXYPROGESTERONE ACETATE
6alpha-Methyl-4-pregnen-17alpha-ol-3,20-dione
6ALPHA-METHYL-4-PREGNENE-3,20-DION-17ALPHA-OL ACETATE
6a-Methyl-17a-hydroxyprogesterone
6a-Methyl-4-pregnen-17a-ol-3,20-dione
6Α-METHYL-17-ACETOXY PROGESTERONE
6Α-methyl-17α-hydroxyprogesterone
6Α-METHYL-17Α-HYDROXYPROGESTERONE ACETATE
6Α-methyl-4-pregnen-17α-ol-3,20-dione
6α-Methyl-4-pregnene-3,20-dion-17α-ol acetate
ADGYN MEDRO
AMEN
Aragest
Aragest 5
Asconale
CBP-1011
CLIMANOR
Clinofem
Clinovir
Colirest
CURRETAB
CYCRIN
Depo-Clinovir
Depo-Prodasone
Depo-Progestin
DEPO-PROGEVERA
Depo-Promone
DEPO-PROVERA
DEPO-PROVERA ONCOLOGY
DEPO-SUBQ PROVERA 104
Depot-Medroxyprogesterone acetate
DMPA
FARLUTAL
FARLUTAL 100
FARLUTAL 200
FARLUTAL 250
FARLUTAL 500
Farlutal inyectable
|
Farlutin
Gestapuran
G-Farlutal
Hematrol
Hydroxymethylprogesterone
hydroxymethylprogesterone|MPA
Hysron
Indivina
LUNELLE
Lutopolar
Lutoral
MAP
Med-Pro
Medroprogesterone Acetate
Medrossiprogesterone
Medrossiprogesterone [Dcit]
Medroxiprogesterona
Medroxiprogesterona [INN-Spanish]
MEDROXIPROGESTERONE ACETATE
Medroxiprogesteronum
MEDROXYACETATE PROGESTERONE
Medroxyprogesteron
Medroxyprogesteron acetate
MEDROXYPROGESTERONE
MEDROXYPROGESTERONE 17-ACETATE
MEDROXYPROGESTERONE ACETATE
Medroxyprogesterone strakan brand
Medroxyprogesteronum
Medroxyprogesteronum [INN-Latin]
Meprate
METHYLACETOXYPROGESTERONE
Methylhydroxyprogesterone
METIGESTRONA
MPA
MPA Gyn 5
Nadigest
Nidaxin
Novo-Medrone
NSC-21171
NSC-26386
Oragest
Perlutex
Perlutex Leo
PREMPRO
Prodasone
Progestalfa
Progevera
PROVERA
Proverone
Ralovera
Repromap
Repromix
SAYANA PRESS
Sirprogen
Sodelut G
Strakan brand OF medroxyprogesterone
TV-46046
Veramix
|
|
16 |
|
Norepinephrine |
Approved |
Phase 3 |
|
51-41-2 |
439260 |
Synonyms:
(-)-(R)-Norepinephrine
(-)-alpha-(Aminomethyl)protocatechuyl alcohol
(−)-arterenol
(-)-Arterenol
(−)-noradrenaline
(-)-Noradrenaline
(−)-norepinephrine
(-)-Norepinephrine
(-)-norepinephrine|Levarterenol®|noradrenaline
(R)-(−)-norepinephrine
(R)-(-)-Norepinephrine
(R)-4-(2-amino-1-hydroxyethyl)-1,2-benzenediol
(R)-noradrenaline
(R)-norepinephrine
4-(2-amino-1-Hydroxyethyl)-1,2-benzenediol
4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol
4-[(1R)-2-AMINO-1-HYDROXYETHYL]BENZENE-1,2-DIOL
4-[(1R)-2-AMINO-1-HYDROXY-ETHYL]BENZENE-1,2-DIOL
4-[(1R)-2-AMINO-1-HYDROXY-ETHYL]PYROCATECHOL
Adrenor
Aktamin
Arterenol
L-2-amino-1-(3,4-Dihydroxyphenyl)ethanol
|
L-3,4-Dihydroxyphenylethanolamine
L-alpha-(Aminomethyl)-3,4-dihydroxybenzyl alcohol
L-Arterenol
Levarterenol
Levoarterenol
Levonor
Levonoradrenaline
Levonorepinephrine
Levophed
L-noradrenaline
L-Norepinephrine
Noradrenalin
Noradrenaline
Nor-adrenaline
Norartrinal
Norepinefrina
Norepinephrine
Norépinéphrine
Norepinephrinum
Norepirenamine
Nor-epirenan
R-NOREPINEPHRINE
Sympathin E
|
|
17 |
|
Cyproterone acetate |
Approved, Investigational |
Phase 3 |
|
427-51-0 |
9880 |
Synonyms:
ANDROCUR
ANDROCUR 10
Androcur®|Cyprostat®|SH-714
CYPROSTAT
CYPROSTAT®
CYPROTERONE
|
CYPROTERONE 17-O-ACETATE
CYPROTERONE ACETATE
DIANE
NSC-81430
SH-714
|
|
18 |
|
(R)-Bicalutamide |
Approved, Experimental |
Phase 3 |
|
90357-06-5, 113299-40-4 |
2375 |
Synonyms:
(-)-Bicalutamide
4'-Cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide
Astra brand OF bicalutamide
AstraZeneca brand OF bicalutamide
BICALUTAMIDA
BICALUTAMIDE
BICALUTAMIDUM
CALUTIDE
Calutide®|Casodex®
|
Casodex
Cosudex
ICI 176334
ICI176,334-1
ICI-176334
KALUMID
ZD7054
Zeneca brand OF bicalutamide
|
|
19 |
|
Buserelin |
Approved, Investigational |
Phase 3 |
|
57982-77-1 |
42615 50225 |
Synonyms:
1-{2-[(2-{[3-(tert-butoxy)-2-[(2-{[1,3-dihydroxy-2-({1-hydroxy-2-[(1-hydroxy-2-{[hydroxy(5-hydroxy-3,4-dihydro-2H-pyrrol-2-yl)methylidene]amino}-3-(1H-imidazol-5-yl)propylidene)amino]-3-(1H-indol-3-yl)propylidene}amino)propylidene]amino}-1-hydroxy-3-(4-hydroxyphenyl)propylidene)amino]-1-hydroxypropylidene]amino}-1-hydroxy-4-methylpentylidene)amino]-5-carbamimidamidopentanoyl}-N-ethylpyrrolidine-2-carboximidate
BUSERELIN
BUSERELIN ACETATE
buserelin acetate|HOE 766|HOE 766A|ICI 123215|Metrelef®|Suprefact®
Buserelina
Busereline
Buserelinum
Etilamide
|
HOE 766
HOE 766A
ICI 123215
METRELEF
SUPRECUR
SUPREFACT
Tiloryth
|
|
20 |
|
Relugolix |
Approved, Investigational |
Phase 3 |
|
737789-87-6 |
10348973 |
Synonyms:
1-(4-(1-(2,6-Difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-D)pyrimidin-6-yl)phenyl)-3-methoxyurea
N-(4-{1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1H,2H,3H,4H-thieno[2,3-D]pyrimidin-6-yl}phenyl)-n'-methoxycarbamimidate
Orgovyx®|Ryeqo® (relugolix-estradiol-norethisterone acetate)|TAK 385|TAK-385
|
Relugolix
TAK 385
TAK-385
|
|
21 |
|
Rucaparib |
Approved, Investigational |
Phase 3 |
|
283173-50-2 |
9931954 |
Synonyms:
AG014699
AG-014699
AG-014699|AG014699|AG14447|PF-01367338|Rubraca®
AG14447
AG-14447
|
AG-14447ag-014699Rucaparib
PF-01367338
Rubraca
RUCAPARIB
Rucaparibum
|
|
22 |
|
Flutamide |
Approved, Investigational |
Phase 2, Phase 3 |
|
13311-84-7 |
3397 |
Synonyms:
1a Brand OF flutamide
4'-Nitro-3'-trifluoromethylisobutyranilide
a,a,a-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide
alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide
Alphapharm brand OF flutamide
Apimid
Apo flutamide
Apo-flutamide
ApoFlutamide
Apogepha brand OF flutamide
Apotex brand OF flutamide
Azupharma brand OF flutamide
Cebatrol
Cell pharm brand OF flutamide
Chephasaar brand OF flutamide
Chimax
Chiron brand OF flutamide
Ciclum brand OF flutamide
Cytamid
Drogenil
Esparma brand OF flutamide
Essex brand OF flutamide
Euflex
Eulexin
Eulexin®|SCH-13521
Eulexine
Fluken
Flulem
Flumid
Fluta 1a pharma
Fluta cell
Fluta gry
Flutacell
Fluta-cell
Fluta-gry
FlutaGRY
Flutamid
Flutamida
Flutamide
Flutamide usp25
Flutamidum
|
Flutamin
Flutandrona
Flutaplex
Flutexin
FTA
Fugerel
Grisetin
Gry brand OF flutamide
Hexal brand OF flutamide
Inibsa brand OF flutamide
Ipsen brand OF flutamide
Juta brand OF flutamide
Kendrick brand OF flutamide
Lemery brand OF flutamide
NFBA
Niftholide
Niftolid
Niftolide
Novo flutamide
Novo-flutamide
NovoFlutamide
Novopharm brand OF flutamide
NSC-215876
Oncosal
Pharmascience brand OF flutamide
PMS Flutamide
PMS-Flutamide
Prasfarma brand OF flutamide
Prostacur
Prostica
Prostogenat
Q Pharm brand OF flutamide
Q-Pharm brand OF flutamide
SCH-13521
Schering brand OF flutamide
Schering plough brand OF flutamide
Schering-plough brand OF flutamide
TAD brand OF flutamide
Tedec meiji brand OF flutamide
Testotard
Α,α,α-trifluoro-2-methyl-4'-nitro-m-propionotoluidide
|
|
23 |
|
Nilutamide |
Approved, Investigational |
Phase 2, Phase 3 |
|
63612-50-0 |
4493 |
Synonyms:
5,5-Dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)- 2,4-imidazolidinedione
5,5-Dimethyl-3-(a,a,a-trifluoro-4-nitro-m-tolyl)hydantoin
5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin
5,5-Dimethyl-3-(α,α,α-trifluoro-4-nitro-m-tolyl)hydantoin
ANADRON
Anandron
Aventis behring brand OF nilutamide
Aventis brand OF nilutamide
|
Hoechst brand OF nilutamide
Nilandron
Nilandron®
Nilutamida
NILUTAMIDE
Nilutamidum
RU-23908
|
|
24 |
|
Salicylic acid |
Approved, Investigational, Vet_approved |
Phase 2, Phase 3 |
|
69-72-7 |
338 |
Synonyms:
2 Hydroxybenzoic acid
2-Carboxyphenol
2-Hydroxybenzenecarboxylate
2-Hydroxybenzenecarboxylic acid
2-HYDROXYBENZOate
2-HYDROXYBENZOIC ACID
Acid, 2-hydroxybenzoic
Acid, O-hydroxybenzoic
Acid, ortho-hydroxybenzoic
Acid, salicylic
ácido salicílico
Acidum salicylicum
Advanced pain relief callus removers
Advanced pain relief corn removers
Bazuka Extra Strength Gel®|salicylate
Clear away wart remover
Compound W
Dr. scholl's callus removers
Dr. scholl's corn removers
Dr. scholl's wart remover kit
Duofil wart remover
Duoplant
Freezone
Ionil
|
Ionil plus
K 537
K 557
O Hydroxybenzoic acid
O-Carboxyphenol
O-Hydroxybenzoate
O-Hydroxybenzoic acid
Ortho hydroxybenzoic acid
Ortho-hydroxybenzoic acid
Phenol-2-carboxylate
Phenol-2-carboxylic acid
Psoriacid-S-stift
Retarder W
Rutranex
SA
Salicylate
Salicylic acid
Salicylic acid collodion
Salicylic acid soap
Saligel
Salonil
Stri-dex
trans-Ver-sal
|
|
25 |
|
Choline |
Approved, Nutraceutical |
Phase 3 |
|
62-49-7 |
305 |
Synonyms:
(2-Hydroxyethyl)trimethyl ammonium
(2-Hydroxyethyl)trimethylammonium
(2-HYDROXYETHYL)TRIMETHYLAZANIUM
(beta-Hydroxyethyl)trimethylammonium
2-HYDROXYETHYL-TRIMETHYL-AMMONIUM
2-HYDROXYETHYL-TRIMETHYL-AZANIUM
2-Hydroxy-N,N,N-trimethylethanaminium
2-Hydroxy-N,N,N-trimethyl-ethanaminium
Bilineurine
Biocolina
Biocoline
Bitartrate, choline
Bursine
Chloride, choline
CHOLINE
Choline bitartrate
Choline cation
Choline chloride
Choline citrate
Choline hydroxide
|
CHOLINE ion
Choline O sulfate
Choline O-sulfate
Cholinum
Citrate, choline
Fagine
Hepacholine
Hormocline
Hydroxide, choline
Lipotril
N,N,N-Trimethylethanolammonium
N,N,N-Trimethylethanol-ammonium
Neocolina
N-Trimethylethanolamine
O-Sulfate, choline
Paresan
Trimethylethanolamine
Vidine
Vitamin J
|
|
26 |
|
Tryptophan |
Approved, Nutraceutical, Withdrawn |
Phase 3 |
|
73-22-3 |
6305 |
Synonyms:
(-)-Tryptophan
(2S)-2-Amino-3-(1H-indol-3-yl)propanoate
(2S)-2-Amino-3-(1H-indol-3-yl)propanoic acid
(L)-Tryptophan
(S)-1H-Indole-3-alanine
(S)-2-AMINO-3-(1H-INDOL-3-YL)PROPANOIC ACID
(S)-2-Amino-3-(3-indolyl)propionic acid
(S)-a-Amino-1H-indole-3-propanoate
(S)-a-Amino-1H-indole-3-propanoic acid
(S)-a-Amino-b-(3-indolyl)-propionate
(S)-a-Amino-b-(3-indolyl)-propionic acid
(S)-a-Amino-b-indolepropionate
(S)-a-Amino-b-indolepropionic acid
(S)-a-Aminoindole-3-propionate
(S)-a-Aminoindole-3-propionic acid
(S)-alpha-Amino-1H-indole-3-propanoate
(S)-alpha-Amino-1H-indole-3-propanoic acid
(S)-alpha-Amino-beta-(3-indolyl)-propionate
(S)-alpha-Amino-beta-(3-indolyl)-propionic acid
(S)-alpha-Amino-beta-indolepropionate
(S)-alpha-Amino-beta-indolepropionic acid
(S)-alpha-Aminoindole-3-propionate
(S)-alpha-Aminoindole-3-propionic acid
(S)-Tryptophan
(S)-Α-amino-1H-indole-3-propanoate
(S)-Α-amino-1H-indole-3-propanoic acid
(S)-Α-amino-β-(3-indolyl)-propionate
(S)-Α-amino-β-(3-indolyl)-propionic acid
1beta-3-Indolylalanine
1-beta-3-Indolylalanine
1H-Indole-3-alanine
2-Amino-3-indolylpropanoate
2-Amino-3-indolylpropanoic acid
3-(1H-indol-3-yl)-L-Alanine
3-indol-3-Ylalanine
Alpha'-amino-3-indolepropionic acid
alpha-Amino-beta-(3-indolyl)-propionic acid
alpha-Aminoindole-3-propionic acid
Alti-Tryptophan
Ardeydorm
Ardeypharm brand OF tryptophan
Ardeytropin
Esparma brand OF tryptophan
GPPE PDR SACH
H-TRP-OH
ICN brand OF tryptophan
Indole-3-alanine
|
Kalma
Kalma brand OF tryptophan
L Tryptophan
L Tryptophan ratiopharm
L-(-)-Tryptophan
L(-)-TRYPTOPHAN
L-(−)-TRYPTOPHAN
l-a-Aminoindole-3-propionic acid
L-alpha-Amino-3-indolepropionic acid
L-alpha-Aminoindole-3-propionic acid
L-b-3-Indolylalanine
L-beta-3-Indolylalanine
Levotryptophan
Lopac-T-0254
L-TRP
L-Tryptofan
L-TRYPTOPHAN
L-Tryptophane
L-Tryptophan-ratiopharm
Lyphan
L-Î’-3-indolylalanine
Merck brand OF tryptophan
Naturruhe
Niddapharm brand OF tryptophan
NSC-13119
Optimax
OPTIMAX WV
Pacitron
Pharmascience brand OF tryptophan
PMS Tryptophan
PMS-Tryptophan
Ratio tryptophan
Ratiopharm brand OF tryptophan
Ratio-tryptophan
Sedanoct
Triptofano
Trofan
Trp
Tryptacin
Tryptan
Tryptophan
Tryptophan metabolism alterations
TRYPTOPHAN, L-
Tryptophane
Tryptophanum
Upsher-smith brand OF tryptophan
W
|
|
27 |
|
Cadexomer iodine |
Experimental |
Phase 2, Phase 3 |
|
94820-09-4 |
|
Synonyms:
|
28 |
|
Bombesin |
Investigational |
Phase 2, Phase 3 |
|
31362-50-2 |
16133800 |
Synonyms:
|
29 |
|
Cyproterone |
|
Phase 3 |
|
2098-66-0 |
5284537 |
Synonyms:
6-Chlor-delta(6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron
6-Chlor-delta(6)-1,2-a-methylen-17-a-hydroxyprogesteron
6-Chlor-δ(6)-1,2-a-methylen-17-a-hydroxyprogesteron
6-Chlor-δ(6)-1,2-α-methylen-17-α-hydroxyprogesteron
Apo-cyproterone
Ciproterona
Ciproterona servycal
|
Ciproterone
CYPROTERONE
Cyproterone acetate
Cyproterone, 1alpha,2 alpha,9 beta,10 alpha-isomer
Cyproteronum
Novo-cyproterone
|
|
30 |
|
Contraceptives, Oral, Hormonal |
|
Phase 3 |
|
|
|
31 |
|
Contraceptives, Oral |
|
Phase 3 |
|
|
|
32 |
|
Contraceptive Agents, Male |
|
Phase 3 |
|
|
|
33 |
|
Serotonin and Noradrenaline Reuptake Inhibitors |
|
Phase 3 |
|
|
|
34 |
|
Antimetabolites |
|
Phase 3 |
|
|
|
35 |
|
Hypolipidemic Agents |
|
Phase 3 |
|
|
|
36 |
|
Lipid Regulating Agents |
|
Phase 3 |
|
|
|
37 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
38 |
|
Nootropic Agents |
|
Phase 3 |
|
|
|
39 |
|
Hormone Antagonists |
|
Phase 3 |
|
|
|
40 |
|
Psychotropic Drugs |
|
Phase 3 |
|
|
|
41 |
|
Antidepressive Agents |
|
Phase 3 |
|
|
|
42 |
|
Contraceptive Agents |
|
Phase 3 |
|
|
|
43 |
|
Triptorelin Pamoate |
|
Phase 3 |
|
|
|
Synonyms:
|
TRIPTORELIN EMBONATE
TRIPTORELIN PAMOATE
|
|
44 |
|
Nonsteroidal Anti-Androgens |
|
Phase 3 |
|
|
|
45 |
|
Hormones |
|
Phase 3 |
|
|
|
46 |
|
Androgens |
|
Phase 3 |
|
|
|
47 |
|
Androgen Antagonists |
|
Phase 3 |
|
|
|
48 |
|
Prolactin Release-Inhibiting Factors |
|
Phase 3 |
|
|
|
49 |
|
Gastrin-Releasing Peptide |
|
Phase 2, Phase 3 |
|
|
91976357 |
50 |
|
Serotonin |
Investigational, Nutraceutical |
Phase 3 |
|
50-67-9 |
5202 |
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5 Hydroxytryptamine
5-HT
5-HT|serotonin
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
5-Hydroxy-tryptamine
|
Antemovis
DS Substance
Enteramin
Enteramine
Hippophaine
Hydroxytryptamine
SEROTONIN
Serotonine
sérotonine
Thrombocytin
Thrombotonin
|
|
Interventional clinical trials:
(show top 50)
(show all 273)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy ) |
Completed |
NCT01661166 |
Phase 4 |
Fesoterodine;Placebo oral tablet |
2 |
Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy |
Completed |
NCT02025361 |
Phase 4 |
intrarectal lidocaine gel;periprostatic nerve blockade |
3 |
Comparison of High-dose- Versus Low-dose-rate Brachytherapy as Monotherapy in the Treatment of Early, Organ Confined Prostate Cancer. |
Unknown status |
NCT02258087 |
Phase 2, Phase 3 |
|
4 |
68Ga-PSMA-11 PET/MRI for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-Risk Prostate Cancer |
Completed |
NCT02678351 |
Phase 2, Phase 3 |
68Ga-PSMA-11 |
5 |
Efficacy and Tolerance of Cyproterone Acetate Versus Medroxyprogesterone Acetate Versus Venlafaxine LP in the Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Patients Treated for a Prostate Adenocarcinoma |
Completed |
NCT01011751 |
Phase 3 |
Cyproterone acetate;Medroxyprogesterone acetate;Venlafaxine;Leuprorelin;Flutamide;Placebo |
6 |
A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer |
Completed |
NCT03739684 |
Phase 3 |
18F-DCFPyL |
7 |
68-Ga PSMA 11 PET/CT for Detection of Recurrent Prostate Cancer After Initial Therapy in Patients With Elevated PSA |
Completed |
NCT02673151 |
Phase 2, Phase 3 |
68Ga-PSMA-11 |
8 |
Staging of Untreated Patients With Very High-risk and High-risk Prostate Carcinoma Utilizing Hybrid C11-choline PET/MR and Pelvic Multiparametric MRI for Personalized Precise Treatment: a Pilot Study |
Completed |
NCT03404648 |
Phase 3 |
C-11 choline PET tracer;Gadobutrol |
9 |
68Ga-PSMA-11 PET in Patients With Prostate Cancer |
Completed |
NCT05197257 |
Phase 3 |
Ga-PSMA-11 |
10 |
68Ga-PSMA PET/CT for Detection of Recurrent Prostate Cancer After Initial Therapy |
Completed |
NCT02940262 |
Phase 3 |
|
11 |
Phase III Multicenter Randomized Trial of Adjuvant Androgen Deprivation in Combination With Three-dimensional Conformal Radiotherapy Doses in High and Intermediate Risk Localized Prostate Cancer. |
Completed |
NCT02175212 |
Phase 3 |
Short term androgen deprivation;Long term androgen deprivation |
12 |
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE) |
Recruiting |
NCT05050084 |
Phase 3 |
Bicalutamide;Buserelin;Darolutamide;Degarelix;Flutamide;Goserelin;Histrelin;Leuprolide;Relugolix;Triptorelin |
13 |
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy |
Recruiting |
NCT04134260 |
Phase 3 |
Apalutamide;Hormone Therapy |
14 |
CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer |
Recruiting |
NCT04455750 |
Phase 3 |
Enzalutamide;Rucaparib camsylate;Placebo;Leuprolide Acetate;Goserelin Acetate;Degarelix |
15 |
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer |
Recruiting |
NCT04446117 |
Phase 3 |
Cabozantinib;Atezolizumab;Abiraterone Acetate;Enzalutamide;Prednisone |
16 |
Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients With Post-ProstaTEctomy Biochemical Recurrence (INDICATE). |
Recruiting |
NCT04423211 |
Phase 3 |
Apalutamide;Goserelin Acetate;Leuprolide Acetate |
17 |
Efficacy, Safety, and Pharmaco-kinetics of Leuprolide Acetate for Injection 3.75mg (Depot) (Leuprorelin) Administered in Subjects With Advanced Adenocarcinoma of Prostate: A Randomized, Active Controlled, Comparative, Open-Label, Multi-Center, Phase 3 Study |
Recruiting |
NCT04914195 |
Phase 3 |
Leuprolide Acetate 3.75 MG/ML |
18 |
A Phase II Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial |
Recruiting |
NCT01411345 |
Phase 2, Phase 3 |
|
19 |
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*) |
Recruiting |
NCT04513717 |
Phase 3 |
Apalutamide;Bicalutamide;Buserelin;Degarelix;Flutamide;Goserelin;Histrelin;Leuprolide;Triptorelin |
20 |
A Randomized Phase III Trial of Hypofractionated Post-prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-prostatectomy Radiation Therapy (COPORT) |
Active, not recruiting |
NCT03274687 |
Phase 3 |
Optional androgen deprivation therapy |
21 |
Phase II-III Trial of Adjuvant Radiotherapy Following Radical Prostatectomy With or Without Adjuvant Docetaxel |
Active, not recruiting |
NCT03070886 |
Phase 2, Phase 3 |
Bicalutamide;Docetaxel;Flutamide;Goserelin Acetate;Leuprolide Acetate;Nilutamide |
22 |
68Ga-RM2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-contributory CT Scans |
Active, not recruiting |
NCT02624518 |
Phase 2, Phase 3 |
Gallium Ga 68-labeled GRPR Antagonist BAY86-7548 |
23 |
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer |
Active, not recruiting |
NCT03367702 |
Phase 3 |
|
24 |
A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse |
Active, not recruiting |
NCT01952223 |
Phase 3 |
Cabazitaxel |
25 |
PALS: Prostate Cancer Active Lifestyle Study |
Terminated |
NCT02454517 |
Phase 3 |
|
26 |
Phase II Randomized Study to Ablate Oligometastatic Prostate Cancer by Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy and to Characterize Its Molecular Phenotype |
Unknown status |
NCT04031378 |
Phase 2 |
Single Dose Radiotherapy (24 Gy) to all detectable lesions followed by adjuvant systemic therapy for 6 months |
27 |
Hedgehog Inhibition as a Non-Castrating Approach to Hormone Sensitive Prostate Cancer: A Phase II Study of Itraconazole in Biochemical Relapse |
Completed |
NCT01787331 |
Phase 2 |
Itraconazole |
28 |
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-Prostatectomy |
Completed |
NCT02849990 |
Phase 2 |
Abiraterone Acetate;Apalutamide;Degarelix;Indomethacin;Prednisone |
29 |
A Prospective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy |
Completed |
NCT00450411 |
Phase 2 |
|
30 |
A Phase II Open Label Trial of Amifostine Plus Fractionated Radiotherapy for Primary Prostate Adenocarcinoma (T1a-T3b, NoMo, PSA>10 ng/ml) to Estimate Acute Grade 2 Genitourinary and Gastrointestinal Toxicity |
Completed |
NCT00003307 |
Phase 2 |
amifostine trihydrate |
31 |
A Trial Of Neoadjuvant Androgen Supression And Dose Escalation Transperineal Ultrasound-Guided Brachytherapy For Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy |
Completed |
NCT00032006 |
Phase 2 |
|
32 |
C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma |
Completed |
NCT01530269 |
Phase 2 |
C11-Sodium Acetate |
33 |
Pentoxifylline, Atorvastatin, and Vitamin E (PAVE) as Treatment for Radiation-Induced Erectile Dysfunction |
Completed |
NCT03830164 |
Phase 2 |
Atorvastatin;Pentoxifylline |
34 |
Evaluation of a 68Ga Small Molecule PSMA Antagonist Produced by Two Different Methods |
Completed |
NCT04685811 |
Phase 1, Phase 2 |
68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron |
35 |
Evaluation of Hypoxia by PET With 18-FluoroMisonidazole During Radiation Therapy of Prostate Cancer |
Completed |
NCT01898065 |
Phase 2 |
18-F-MISO |
36 |
A Phase II Randomized Study of Enzalutamide+Leuprolide Versus Enzalutamide+Leuprolide+Abiraterone Acetate+Prednisone as Neoadjuvant Therapy for HIgh-Risk Prostate Cancer Undergoing Prostatectomy |
Completed |
NCT02268175 |
Phase 2 |
Enzalutamide;Abiraterone Acetate;Prednisone;Leuprolide Acetate |
37 |
A Pre-Operative Study to Assess the Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence |
Completed |
NCT03279250 |
Phase 2 |
Abiraterone Acetate;Apalutamide;Prednisone |
38 |
Biomarker-Driven Phase-2 Study of Combined Immune Checkpoint Blockade for AR-V7-Expressing Metastatic Castration-Resistant Prostate Cancer (STARVE-PC) |
Completed |
NCT02601014 |
Phase 2 |
Enzalutamide |
39 |
Neoadjuvant Androgen Depletion in Combination With Vorinostat Followed by Radical Prostatectomy for Localized Prostate Cancer: Total Androgen-Receptor Gene Expression Targeted Therapy (TARGET) |
Completed |
NCT00589472 |
Phase 2 |
Bicalutamide;Goserelin Acetate;Leuprolide Acetate;Vorinostat |
40 |
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence |
Completed |
NCT03396874 |
Phase 2 |
68Ga-PSMA |
41 |
A Phase II Pilot Study of Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy. |
Completed |
NCT00183924 |
Phase 2 |
Estramustine;Docetaxel;Carboplatin |
42 |
A Phase II Study of Trilostane for Androgen-Independent Prostate Cancer |
Completed |
NCT00181597 |
Phase 2 |
Trilostane;Hydrocortisone |
43 |
A Phase II Immunotherapeutic Trial: Combination Androgen Ablative Therapy and CTLA-4 Blockade as a Treatment for Advanced Prostate Cancer |
Completed |
NCT00170157 |
Phase 2 |
Bicalutamide;Flutamide;Goserelin Acetate;Ipilimumab;Leuprolide Acetate |
44 |
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies. |
Completed |
NCT03365791 |
Phase 2 |
|
45 |
A Pilot Trial to Explore the Link Between Immunological Changes, Efficacy, Safety, and Tolerability of Durvalumab (MEDI4736) Plus Tremelimumab in Chemotherapy-Naïve Men With Metastatic Castration-Resistant Prostate Cancer (CRPC) |
Completed |
NCT03204812 |
Phase 2 |
|
46 |
A Randomized Phase II Study of Androgen Deprivation Combined With IMC-A12 Versus Androgen Deprivation Alone for Patients With New Hormone Sensitive Metastatic Prostate Cancer |
Completed |
NCT01120236 |
Phase 2 |
Bicalutamide;Goserelin Acetate;Leuprolide Acetate |
47 |
Impact of 68GA-PSMA-11 PET/CT on Initial and Subsequent Treatment Strategies of Patients With Prostate Cancer |
Completed |
NCT04050215 |
Phase 2 |
Gallium Ga 68-labeled PSMA-11 |
48 |
Phase I/II Trial of Anti-IGF-IR Monoclonal Antibody IMC-A12 Plus mTOR Inhibitor Temsirolimus (CCI-779) in Metastatic Castration-Resistant Prostate Cancer (CRPC) |
Completed |
NCT01026623 |
Phase 1, Phase 2 |
Temsirolimus |
49 |
Surgery Combined With IMRT-IGRT in Locally-advanced Prostate Cancers |
Completed |
NCT01148069 |
Phase 2 |
|
50 |
Phase IIA, Randomized Placebo-Controlled Trial of Single High Dose Cholecalciferol and Daily Genistein (G-2535) Versus Placebo in Men With Early Stage Prostate Cancer Undergoing Prostatectomy |
Completed |
NCT01325311 |
Phase 2 |
Cholecalciferol;Genistein |
|